Professor
Along with my team, I am investigating molecular mechanisms and targeted therapy of esophageal squamous cell carcinoma (ESCC). Our long-term goal is to develop NRF2 inhibitors for targeted therapy of human ESCC carrying NRF2 mutations, and “benign cell boosters” for prevention of ESCC in high-risk patients.
Prior to Coriell, I was the Glaxo Distinguished Professor of Biomedical Science in the Julius L. Chambers Biomedical/Biotechnology Research Institute (BBRI), North Carolina Central University (NCCU), and Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill (UNC-CH).
I received my medical training at Peking University Health Science Center of China and first worked as a research assistant and resident orthopedic surgeon before earning my PhD in Biochemistry from Rutgers University in New Brunswick, New Jersey. My postdoctoral training was also completed at Rutgers University.
EducationPostdoctoral Associate - Rutgers University, New Brunswick, New Jersey PhD - Rutgers University, New Brunswick, New Jersey Bachelor of Medicine (MD equivalent) - Peking University Health Sciences Center (formerly Beijing Medical University), Beijing, P.R. China |
Publications |
